We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
GW Pharm. | LSE:GWP | London | Ordinary Share | GB0030544687 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 735.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMGWP
RNS Number : 9985P
GW Pharmaceuticals PLC
24 November 2016
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) -------------------------------------------------- 1. Identity of the issuer or GW Pharmaceuticals PLC the underlying issuer of existing shares to which voting rights are attached: (ii) ------------------------------------------------------------- ------------------------------------- 2 Reason for the notification (please tick the appropriate box or boxes): ---------------------------------------------------------------------------------------------------- An acquisition or disposal of voting rights ----------------------------------------------------------------- --------------------------------- An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ----------------------------------------------------------------- --------------------------------- An acquisition or disposal of instruments with x similar economic effect to qualifying financial instruments ----------------------------------------------------------------- --------------------------------- An event changing the breakdown of voting rights ----------------------------------------------------------------- --------------------------------- Other (please specify): --------------------------------------------------------- ------ --------------------------------- 3. Full name of person(s) The Goldman Sachs Group, Inc. subject to the notification obligation: (iii) ----------------------------------------------------------- --------------------------------------- 4. Full name of shareholder(s) Goldman Sachs International (if different from 3.):(iv) Goldman, Sachs & Co. Goldman Sachs Asset Management, L.P. ----------------------------------------------------------- --------------------------------------- 5. Date of the transaction 18 November 2016 and date on which the threshold is crossed or reached: (v) ----------------------------------------------------------- --------------------------------------- 6. Date on which issuer 22 November 2016 notified: ----------------------------------------------------------- --------------------------------------- 7. Threshold(s) that is/are Below 3% crossed or reached: (vi, vii) ----------------------------------------------------------- --------------------------------------- 8. Notified details: ------------------------------------------------------------------------------------------------------------ A: Voting rights attached to shares (viii, ix) ------------------------------------------------------------------------------------------------------------ Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE ---------------- ------------------------------ ---------------------------------------------------------- Number Number Number Number of % of voting of of of voting rights (x) Shares Voting shares rights Rights ---------------- -------------- -------------- -------- ----------------------- ----------------------- Direct Direct Indirect Direct Indirect (xi) (xii) ---------------- -------------- -------------- -------- ------- -------------- ------- -------------- Below Below GB0030544687 94,532 94,532 3% 3% -------------- -------------- -------- ------- -------------- ------- -------------- B: Qualifying Financial Instruments ------------------------------------------------------------------------------------------------------------ Resulting situation after the triggering transaction ------------------------------------------------------------------------------------------------------------ Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that rights instrument (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. ---------------- -------------- ------------------------ ----------------------- ----------------------- Below 3% Below 3% ---------------- -------------- ------------------------ ----------------------- ----------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) ---------------------------------------------------------------------------------------- Resulting situation after the triggering transaction ---------------------------------------------------------------------------------------- Type of financial Exercise Expiration Exercise/ Number % of voting instrument price date Conversion of voting rights (xix, period rights xx) instrument refers to ------------------ --------- ----------- ------------ ------------ ---------------- Nominal Delta ------------------ --------- ----------- ------------ ------------ -------- ------ Below Below 3% 3% ------------------ --------- ----------- ------------ ------------ -------- ------ ------------------------------------------------------------------------------------------------------------ Total (A+B+C) ------------------------------------------------------------------------------------------------------------ Number of voting rights Percentage of voting rights ------------------------------------------------ ---------------------------------------------------------- Below 3% Below 3% ------------------------------------------------ ---------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) ---------------------------------------------------------------------------------------- N/A Proxy Voting: ---------------------------------------------------------------------------------------- 10. Name of the proxy holder: N/A ------------------------------------------------------- ------------------------------- 11. Number of voting rights proxy N/A holder will cease to hold: ------------------------------------------------------- ------------------------------- 12. Date on which proxy holder will N/A cease to hold voting rights: ------------------------------------------------------- ------------------------------- General email contact: 13. Additional information: shareholderdisclosures@gs.com ------------------------------------------------------- ------------------------------- 14. Contact name: Joanna Foley ------------------------------------------------------- ------------------------------- 15. Contact telephone number: +44 207 051 9996 ------------------------------------------------------- -------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLEAPFDAEAKFFF
(END) Dow Jones Newswires
November 24, 2016 02:30 ET (07:30 GMT)
1 Year Gw Pharmaceuticals Chart |
1 Month Gw Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions